Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00291668|
Recruitment Status : Completed
First Posted : February 14, 2006
Last Update Posted : March 6, 2015
UCB Japan Co. Ltd.
Information provided by (Responsible Party):
UCB Pharma ( UCB Japan Co. Ltd. )
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||November 2007|
|Actual Study Completion Date :||November 2007|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
February 8, 2018 ||September 28, 2018|